SRNA Has Partnered with NeurologyLive

SRNA is excited to expand our education and professional development efforts for clinicians through a partnership with NeurologyLive. NeurologyLive’s goal is to deliver relevant information to healthcare professionals treating neurological diseases to help them provide the best patient care possible. Through a strategic partnership with NeurologyLive, we can work together to identify and develop content on their multi-channel platform to help educate and inform healthcare professionals about rare neuroimmune disorders.

Together, we have developed a series of podcasts, videos, and articles for medical professionals in a library that will continue to grow. Below are some of the resources that have come from our partnership so far:

• Acute Flaccid Myelitis (AFM) was highlighted in the Mind Moments® podcast with a discussion on the latest research and disease management strategies related to AFM. Learn more.

• Olwen C. Murphy, MBBCh, and Matthew R. Vogt, MD, PhD, discussed the current clinical understanding of Acute Flaccid Myelitis (AFM) and the need to recognize this condition amid the “peak” months of infection. Learn more.

• Carlos A. Pardo-Villamizar, MD, provided an in-depth look at the 2022 Rare Neuroimmune Disorders Symposium (RNDS) and highlighted the patient-centric theme of the event. Learn more.

• Rebecca Whitney, SRNA’s Associate Director of Programs and Community Support, wrote an article about the 2022 RNDS. Learn More.

• Experts including Brenda Banwell, MD, Sean Pittock, MD, and Michael Levy, MD, PhD, covered topics including rare neuroimmune disorders diagnosis, presentation, and treatment decision differences in an SRNA Roundtable Discussion. Learn more.

• John Chen, MD, PhD spoke about improvements in awareness of NMOSD and Optic Neuritis. Dr. Chen, a neuroophthalmologist at Mayo Clinic, provided context on the importance of raising awareness for NMOSD and the signs that precede clinical events. Learn more.

• Anastasia Vishnevetsky, MD was spotlighted for a NeuroVoices segment on Key Research Needs and the Potential for FDA-Approved Treatments for MOGAD. Dr. Vishnevetsky, an immunology fellow at Brigham and Women’s Hospital, provided insight on the latest research initiatives in MOG antibody disease, including the potential for the first FDA-approved therapy. Learn more.

If you are interested in contributing to a segment on rare neuroimmune disorders for NeurologyLive, please contact Krissy Dilger at [email protected].